JP2021523941A5 - - Google Patents
Info
- Publication number
- JP2021523941A5 JP2021523941A5 JP2021513005A JP2021513005A JP2021523941A5 JP 2021523941 A5 JP2021523941 A5 JP 2021523941A5 JP 2021513005 A JP2021513005 A JP 2021513005A JP 2021513005 A JP2021513005 A JP 2021513005A JP 2021523941 A5 JP2021523941 A5 JP 2021523941A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridine
- oxy
- piperidine
- dichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670050P | 2018-05-11 | 2018-05-11 | |
| US62/670,050 | 2018-05-11 | ||
| PCT/EP2019/062098 WO2019215341A1 (en) | 2018-05-11 | 2019-05-10 | Furin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523941A JP2021523941A (ja) | 2021-09-09 |
| JP2021523941A5 true JP2021523941A5 (enExample) | 2022-05-18 |
| JP7350061B2 JP7350061B2 (ja) | 2023-10-02 |
Family
ID=66597541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513005A Active JP7350061B2 (ja) | 2018-05-11 | 2019-05-10 | フューリンインヒビター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11773078B2 (enExample) |
| EP (1) | EP3790871B1 (enExample) |
| JP (1) | JP7350061B2 (enExample) |
| KR (1) | KR102823187B1 (enExample) |
| CN (1) | CN112384509B (enExample) |
| AU (1) | AU2019267166C1 (enExample) |
| BR (1) | BR112020022961A2 (enExample) |
| CA (1) | CA3099863A1 (enExample) |
| IL (2) | IL278642B2 (enExample) |
| MX (1) | MX2020012034A (enExample) |
| SG (1) | SG11202010914YA (enExample) |
| WO (1) | WO2019215341A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| WO2021097002A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyrimidines for treating infectious diseases |
| CA3157892A1 (en) * | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
| WO2021097008A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyridines for treating infectious diseases |
| CA3173921A1 (en) | 2020-04-02 | 2021-10-07 | Bp Asset V, Inc. | Furin inhibitors for treating coronavirus infections |
| FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
| JP2024506291A (ja) * | 2021-02-03 | 2024-02-13 | ビーピー アセット ヴイ，インコーポレーテッド | 吸入用のフューリンインヒビターの製剤 |
| CN114853640A (zh) * | 2022-05-12 | 2022-08-05 | 马鞍山昂扬新材料科技有限公司 | 2-溴乙基磺酸钠的制备方法 |
| WO2024073576A1 (en) * | 2022-09-29 | 2024-04-04 | Bp Asset V, Inc. | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof |
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
| CN119119096B (zh) * | 2024-09-09 | 2025-09-16 | 郑州药领医药科技有限公司 | 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1646160A (zh) | 2002-03-13 | 2005-07-27 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| ATE527250T1 (de) | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
| WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| CA2586086A1 (en) * | 2004-07-23 | 2006-01-23 | Robert E.(Deceased) Smith | Furin inhibitors |
| CA2579143A1 (en) * | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| CA2687024A1 (en) | 2007-05-09 | 2009-02-19 | Burnham Institute For Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| AU2009216851B2 (en) * | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| CN106167483B (zh) | 2010-10-18 | 2019-02-15 | 塞伦尼斯医疗控股有限公司 | 可用于胆固醇动员的化合物、组合物和方法 |
| WO2013138666A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| WO2013138665A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| US9353066B2 (en) * | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| WO2014152716A1 (en) | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| WO2016144702A1 (en) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107441094B (zh) | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| CA3157892A1 (en) | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
-
2019
- 2019-05-10 CN CN201980046497.1A patent/CN112384509B/zh active Active
- 2019-05-10 WO PCT/EP2019/062098 patent/WO2019215341A1/en not_active Ceased
- 2019-05-10 IL IL278642A patent/IL278642B2/en unknown
- 2019-05-10 JP JP2021513005A patent/JP7350061B2/ja active Active
- 2019-05-10 IL IL302997A patent/IL302997B2/en unknown
- 2019-05-10 MX MX2020012034A patent/MX2020012034A/es unknown
- 2019-05-10 KR KR1020207035245A patent/KR102823187B1/ko active Active
- 2019-05-10 BR BR112020022961-0A patent/BR112020022961A2/pt unknown
- 2019-05-10 CA CA3099863A patent/CA3099863A1/en active Pending
- 2019-05-10 EP EP19725058.2A patent/EP3790871B1/en active Active
- 2019-05-10 SG SG11202010914YA patent/SG11202010914YA/en unknown
- 2019-05-10 AU AU2019267166A patent/AU2019267166C1/en active Active
- 2019-05-10 US US17/054,491 patent/US11773078B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278642B1 (en) | Purine inhibitors | |
| NL2000323C2 (nl) | Pyrimidine-derivaten. | |
| ES2654051T3 (es) | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas | |
| EP3183247B9 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| ES2534335T3 (es) | Compuestos macrocíclicos como inhibidores de la Trk cinasa | |
| JP6585158B2 (ja) | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 | |
| JP5629324B2 (ja) | ピロロ［２，３−ｄ］ピリミジン化合物 | |
| RU2399620C2 (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| ES2590929T3 (es) | Derivados de bencilsulfonamida útiles como inhibidores de MOGAT-2 | |
| TW202523297A (zh) | 用於治療癌症的咪唑並嘧啶化合物 | |
| JP2013514356A (ja) | ピロロ［２，３−ｄ］ピリミジン化合物 | |
| RS63981B1 (sr) | Selektivni inhibitori jak1 | |
| JP2023552864A5 (enExample) | ||
| JP2018536684A (ja) | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 | |
| CN114746414A (zh) | 氮杂-喹啉化合物及其用途 | |
| JP2017519023A (ja) | ３−置換２−アミノ−インドール誘導体 | |
| US20230373935A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP2023503852A5 (enExample) | ||
| WO2024259171A9 (en) | Keap1 inhibitors and uses thereof | |
| JP2023521032A5 (enExample) | ||
| RU2020140798A (ru) | Ингибиторы фурина | |
| US12257243B2 (en) | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | |
| HK40077297A (en) | Aza-quinoline compounds and uses thereof | |
| EP4727945A1 (en) | 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer | |
| WO2026085375A1 (en) | Compositions and methods for inhibiting egfr |